AI Generated Image
Who got Eli Lilly retatrutide; Pfizer lung cancer trial: The Readout
statnews.com • • business
Key Points:
- Eli Lilly and the FDA have granted a single individual access to the company's next-generation obesity drug under the FDA’s “compassionate use” program.
- This compassionate use allowance is notable as it permits access to an investigational drug prior to full regulatory approval.
- The development highlights the potential of Lilly’s obesity candidate as a promising new treatment option.
- The case underscores ongoing collaboration between pharmaceutical companies and regulators to provide early access to innovative therapies.
